Astria Therapeutics (ATXS) announced final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from ...

Researchers identified 13 plasma proteins linked to brain aging, uncovering dynamic patterns and biomarkers for early ...

Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on KalVista Pharmaceuticals (KALV – Research Report). The ...

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

Brain age gap (BAG) is a useful metric because it predicts one’s age-adjusted vulnerability to a range of neurological disorders, such as AD, dementia, and stroke. Although brain age may indeed ...

In 2024, startups saw a notable resurgence in large-scale funding rounds. By May, over 100 startups had secured funding ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October ...

Equities research analysts at HC Wainwright lowered their FY2029 EPS estimates for KalVista Pharmaceuticals in a research ...

In a phase 1 trial, Sebetralstat was shown to be able to suppress plasma kallikrein activity nearly completely. A single 600 mg dose of Sebetralstat produced a 98% inhibition of plasma kallikrein ...

After hours: December 10 at 5:11:36 PM EST Loading Chart for RZLT ...

Cantor Fitzgerald restated their overweight rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a report released on Monday morning,Benzinga reports. KALV has been the subject ...